Ubivac, LLC

Portland, OR 97213

SBIR Award Summary

Total Number of Awards 8
Total Value of Awards $3.82MM
First Award Date 06/01/06
Most Recent Award Date 07/01/14

Key Personnel

Last Name Name Awards Contact
Aung Sandra Aung 5
Hilton Traci Hilton 3

8 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PAR-10-286
Budget: 07/01/14 - 08/31/14

DESCRIPTION (provided by applicant): PROJECT SUMMARY Although prophylactic vaccines have potential for prevention of high risk human papilloma virus (HPV) infection they have no therapeutic efficacy. It has been estimated that there will be no measurable decline of HPV- associated tumors before 2040 (Hellner et al., 2011). Likewise, other HPV-as...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-050
Budget: 09/11/13 - 08/31/14

DESCRIPTION (provided by applicant): Recent advances in cellular immunology have revolutionized our understanding of antigen processing and presentation. UBIVAC, LLC, has an exclusive option on technology (patent pending) that exploits these developments that was developed by Dr. Hong-Ming Hu. Further, the founders of UBIVAC (Drs. Hu and Fox) an...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PAR-10-286
Budget: 07/01/13 - 06/30/14

DESCRIPTION (provided by applicant): PROJECT SUMMARY Although prophylactic vaccines have potential for prevention of high risk human papilloma virus (HPV) infection they have no therapeutic efficacy. It has been estimated that there will be no measurable decline of HPV- associated tumors before 2040 (Hellner et al., 2011). Likewise, other HPV-as...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-050
Budget: 09/01/12 - 08/31/13

DESCRIPTION (provided by applicant): Recent advances in cellular immunology have revolutionized our understanding of antigen processing and presentation. UBIVAC, LLC, has an exclusive option on technology (patent pending) that exploits these developments that was developed by Dr. Hong-Ming Hu. Further, the founders of UBIVAC (Drs. Hu and Fox) an...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-050
Budget: 09/01/11 - 08/31/12

DESCRIPTION (provided by applicant): Recent advances in cellular immunology have revolutionized our understanding of antigen processing and presentation. UBIVAC, LLC, has an exclusive option on technology (patent pending) that exploits these developments that was developed by Dr. Hong-Ming Hu. Further, the founders of UBIVAC (Drs. Hu and Fox) an...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-050
Budget: 09/01/10 - 08/31/11

DESCRIPTION (provided by applicant): Recent advances in cellular immunology have revolutionized our understanding of antigen processing and presentation. UBIVAC, LLC, has an exclusive option on technology (patent pending) that exploits these developments that was developed by Dr. Hong-Ming Hu. Further, the founders of UBIVAC (Drs. Hu and Fox) an...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-050
Budget: 09/01/09 - 08/31/10

DESCRIPTION (provided by applicant): Recent advances in cellular immunology have revolutionized our understanding of antigen processing and presentation. UBIVAC, LLC, has an exclusive option on technology (patent pending) that exploits these developments that was developed by Dr. Hong-Ming Hu. Further, the founders of UBIVAC (Drs. Hu and Fox) an...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 06/01/06 - 05/31/08

DESCRIPTION (provided by applicant): A major hurdle for the development of effective cancer vaccines is the inability of most currently available cancer vaccines to induce a robust immune responses against a broad spectrum of tumor antigens. It has been well-established that the induction of T-cell mediated antitumor immune responses is critical...